Litcius/Paper detail

Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

Andrea C. Tricco, Huda Ashoor, Jesmin Antony, Zachary Bouck, Myanca Rodrigues, Ba’ Pham, Paul A. Khan, Vera Nincic, Nazia Darvesh, Fatemeh Yazdi, Marco Ghassemi, John D. Ivory, Areti Angeliki Veroniki, Catherine Yu, Lorenzo Moja, Sharon E. Straus

2021Journal of General Internal Medicine31 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMeta-analysisInsulinHypoglycemiaInternal medicineInsulin glargineRandomized controlled trialType 1 diabetesOdds ratioBiosimilarType 2 Diabetes MellitusDiabetes mellitusAdverse effectEndocrinologyDiabetes Management and ResearchBiosimilars and Bioanalytical MethodsDiabetes and associated disorders
Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis | Litcius